Latest News for ERNA
Ernexa Therapeutics (NASDAQ: ERNA - Get Free Report) and Aditxt (NASDAQ: ADTX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability. Insider and Institutional Ownership 70.6% of Ernexa Therapeutics
Ernexa Therapeutics Inc. (NASDAQ: ERNA - Get Free Report) shares were down 11.4% during trading on Monday. The company traded as low as $0.2703 and last traded at $0.2703. Approximately 1,070,042 shares were traded during trading, a decline of 65% from the average daily volume of 3,040,254 shares. The stock had previously closed at $0.3051.
Live video webcast with Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, on Wednesday, February 25th at 4:00 PM ET
CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (Nasdaq: ERNA) (“Ernexa” or the “Company”), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the pricing of a best-efforts registered public offering of 21,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to…
Access the “What This Means” segment here
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ERNA.
U.S. House Trading
No House trades found for ERNA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.